Chemokine receptor 7 (CCR7)-expression and IFNγ production define vaccine-specific canine T-cell subsets

Veterinary Immunology and Immunopathology
Ashley N Hartley, Rick L Tarleton

Abstract

Canines suffer from and serve as strong translational animals models for many immunological disorders and infectious diseases. Routine vaccination has been a mainstay of protecting dogs through the stimulation of robust antibody responses and expansion of memory T-cell populations. Commercially available reagents and described techniques are limited for identifying and characterizing canine T-cell subsets and evaluating T-cell-specific effector function. To define reagents for delineating naïve versus activated T-cells and identify antigen-specific T-cells, we tested anti-human and anti-bovine T-cell specific cell surface marker reagents for cross-reactivity with canine peripheral blood mononuclear cells (PBMCs. Both CD4(+) and CD8(+) T-cells from healthy canine donors showed reactivity to CCL19-Ig, a CCR7 ligand, and coexpression with CD62L. An in vitro stimulation with concanavalin A validated downregulation of CCR7 and CD62L expression on stimulated healthy control PBMCs, consistent with an activated T-cell phenotype. Anti-IFNγ antibodies identified antigen-specific IFNγ-producing CD4(+) and CD8(+) T-cells upon in vitro vaccine antigen PBMC stimulation. PBMC isolation within 24h of sample collection allowed for efficienT-cel...Continue Reading

References

Aug 1, 1992·Veterinary Immunology and Immunopathology·D H Gebhard, P B Carter
Nov 1, 1990·Tissue Antigens·P F MooreD M Danilenko
Mar 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·T K KishimotoE C Butcher
Oct 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·D L UrdalS K Dower
Mar 1, 1996·Veterinary Pathology·M CaniattiP F Moore
Oct 1, 1996·Veterinary Immunology and Immunopathology·H GalkowskaU Wojewodzka
Dec 10, 1999·Veterinary Immunology and Immunopathology·J MorenoJ Alvar
Jul 4, 2001·The Journal of Experimental Medicine·D C HargreavesJ G Cyster
Jul 20, 2002·Veterinary Immunology and Immunopathology·L G PedersenB Aasted
Oct 22, 2002·Acta Tropica·Paulo Marcos da Matta GuedesMaria Terezinha Bahia
Jul 5, 2003·Veterinary Immunology and Immunopathology·Kate E CreevyDennis D Hickstein
Aug 24, 2005·Nature Immunology·Gudrun F DebesEugene C Butcher
Sep 12, 2006·Nature Biotechnology·Chand KhannaStephen Withrow
Jul 24, 2007·Veterinary Immunology and Immunopathology·Hans-Joachim SchuberthMartin Faldyna
Feb 4, 2009·Proceedings of the National Academy of Sciences of the United States of America·Tomoyuki AwanoJoan R Coates
Jun 12, 2009·The Journal of Investigative Dermatology·Rosanna Marsella, Giampiero Girolomoni
Jan 14, 2011·Veterinary Immunology and Immunopathology·C L FellmanA J Mackin

❮ Previous
Next ❯

Citations

Dec 30, 2016·Journal for Immunotherapy of Cancer·Jiwon S ParkRobert J Canter
Nov 27, 2018·ILAR Journal·Nana H OvergaardGregers Jungersen
Dec 12, 2019·Frontiers in Immunology·Friederike V RabigerGottfried Alber
Mar 9, 2021·Frontiers in Immunology·Iwona Monika SzopaKinga Majchrzak-Kuligowska
Jun 4, 2018·Developmental and Comparative Immunology·Sita S WithersRobert B Rebhun

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.